Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts

Trial Profile

Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms INTEGRATE
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 01 Jun 2017 Results published in the Infectious Diseases and Therapy.
    • 08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top